NCT04655599View on ClinicalTrials.gov

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 29, 2021

Primary Completion Date

April 13, 2021

Study Completion Date

April 13, 2021

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

Olorinab

Olorinab tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.

DRUG

Placebo

Olorinab matching placebo tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors
All Listed Sponsors
lead

Arena Pharmaceuticals

INDUSTRY

NCT04655599 - Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome | Biotech Hunter | Biotech Hunter